TNFSF10 and acute lymphoblastic leukemia: A validated CDK7 inhibitor BS-181 at a pharmacological dose was found to exert antitumor activity primarily through cell cycle arrest in the G1 phase and induction of the extrinsic TRAIL/DR5 upregulation-mediated apoptosis in human T-ALL Jurkat cells (clone A3) with an IC50 value of 14.5 μM.